Sangamo Therapeutics Inc 2026年季度报告

FORM 10-Q________________________________________________ (Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026OR☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period fromtoCommission file number 000-30171________________________________________________ SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)________________________________________________ 68-0359556(I.R.S. EmployerIdentification No.) Delaware (State or other jurisdiction ofincorporation or organization) 501 Canal Blvd., Richmond, California, 94804(Address of principal executive offices) (Zip Code) (510) 970-6000(Registrant’s telephone number, including area code)________________________________________________________________________________________________ Indicate by check mark whether the registrant (1)has filed all reports required to be filed by section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and(2)has been subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reportingcompany” and “emerging growth company” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒As of May11, 2026, 414,288,847 shares of the issuer’s common stock, par value $0.01 per share, were outstanding. (*) On April 28, 2026, Sangamo Therapeutics, Inc. (the “Company”) received a written notification from the Nasdaq Stock MarketLLC (“Nasdaq”) of its determination to delist the Company’s common stock as a result of the Company’s ongoing failure to comply withNasdaq’s minimum bid price requirement. The Company’s common stock was suspended from trading on Nasdaq, and began trading on theOTCQB Venture Market, on May 5, 2026. The Company has requested a hearing before a Nasdaq Hearings Panel for the purposes ofappealing the delisting determination. The timely request for a hearing will stay delisting but did not stay the trading suspension of theCompany’s common stock. INDEX SANGAMO THERAPEUTICS, INC. PART I. FINANCIAL INFORMATION Financial StatementsCondensed Consolidated Balance SheetsCondensed Consolidated Statements of OperationsCondensed Consolidated Statements of Comprehensive LossCondensed Consolidated Statements of Stockholders’ Equity(Deficit)Condensed Consolidated Statements of Cash FlowsNotes to Condensed Consolidated Financial StatementsManagement’s Discussion and Analysis of Financial Condition and Results of OperationsQuantitative and Qualitative Disclosures about Market RiskControls and Procedures Item1. Item2.Item3.Item4. PART II. OTHER INFORMATION Item1.Legal ProceedingsItem1A.Risk FactorsItem2.Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity SecuritiesItem3.Defaults Upon Senior SecuritiesItem4.Mine Safety DisclosuresItem5.Other InformationItem6.Exhibits SIGNATURES Unless otherwise indicated or the context suggests otherwise, references in this Quarterly Report on Form 10-Q, or Quarterly Report,to “Sangamo,” “the Company,” “we,” “us,” and “our” refer to Sangamo Therapeutics, Inc. and our subsidiaries. Any third-party trade names, trademarks and service marks appearing in this Quarterly Report are the property of their respectiveholders. Solely for convenience, trademarks and trade names referred to in this Quarterly Report may appear without the ® orsymbols,but such references are not intended to indicate in any way that the Company will not assert, to the fullest extent under applicable law, itsrights or the rights of the applicable licensor to these trademarks and trade names. The Company does not intend its use or display of otherentities’ trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of the Company by, any otherentity.TM SPECIAL NOTEREGARDING FORWARD-LOOKING STATEMENTS Some statements contained in this report are “forwar